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Toolsa b s t r a c t
Malaria in the Asia-Pacific region has been targeted for elimination by the year 2030. This article asks the
question, ‘‘by what means?” in the context of proven technical strategies and tools against key challenges
imposed by the distinct character of the Asia-Pacific malaria problem. The misperception of malaria in
the Asia-Pacific region as a less serious but otherwise essentially similar problem to African malaria lulls
us into rote application of the same tools and strategies. Those now mitigating the harm done by malaria
in Africa will not suffice to eliminate malaria in the Asia-Pacific region – these tasks and the problems are
fundamentally distinct. This article describes the singular characteristics of Asia-Pacific malaria and the
bearing of those upon the technical strategy of malaria elimination. Most of the tools needed for that
endeavour do not yet exist and spirited calls for elimination within the next 14 years may discourage
the patience and investments needed to conceive, optimise and validate them.
 2016 The Author. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Eliminating malaria
The diverse community engaged in mitigating the harm done
by malaria – and to ultimately eliminate it – focuses on the
extraordinary burdens of morbidity and mortality caused by Plas-
modium falciparum on the African continent. The technical strate-
gies for doing so now implemented there came with compelling
bodies of scientific evidence demonstrating positive impacts.
Indeed, recent estimates of morbidity and mortality across Africa
point to profound progress having been achieved in the past dec-
ade (Bhatt et al., 2015). These gains occurred after the extraordi-
nary scaling up of specific evidence-based interventions – rapid
diagnostic tests (RDTs), artemisinin combined therapies (ACTs),
long-lasting insecticide-treated bed nets (LLINs), and indoor
residual insecticide spraying (IRS) (Smithson et al., 2015). In
addition to the less tangible but vitally important assets of social
awareness, community engagement, political will, and historic
generosity, those commodities compose the physical tools
against malaria. Moreover, the research community has
endeavoured for over 40 years to field a vaccine aimed at
protecting highly vulnerable African infants and small children
from poor outcomes of infection. The most advanced vaccine,
RTS, S, reduced the risk of febrile clinical attacks of relatively highparasitemia, but not infection per se or death (Greenwood and
Doumbo, 2016).
In the African context RDTs, ACTs, LLINs and IRS surely mitigate
harm, and a vaccine that prevents illness and death would save
very many lives. However, few of these tools rationally align with
strategies to wholly eliminate malaria. In a tactical and strategic
sense, mitigating the harm of high transmission is quite distinct
from eliminating its causative agents where unstable or low trans-
mission prevails. This distinction may be lost upon non-technical
advocates for eliminating malaria, but it is crucially important to
grasp.
In 2007 Bill and Melinda Gates implored the malaria commu-
nity to adopt a strategy of eliminating malaria rather than learning
to live with it in perpetuity by mitigation of harm alone (Tanner
and de Savigny, 2008). The World Health Organization (WHO)
embraced and formalised the concept in 2008, and later wisely
specified epidemiological contexts where elimination goals may
be realistically achieved. Those appropriately excluded much of
holo-endemic sub-Saharan Africa and high transmission areas in
southern and southeastern Asia. Heavily malarious areas first must
reduce transmission to low levels before considering elimination
as a goal of defined milestones. In contrast, the many nations in
the Asia-Pacific region having unstable or hypo- to meso-
endemic malaria seemed suited to an elimination agenda. By
2009 many had formally adopted elimination goals and joined
the Asia-Pacific Malaria Elimination Network (Gosling et al.,
2012). In 2013 representative heads of state formed theoi.org/
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of malaria from the Asia Pacific by 2030 as their collective
goal (http://aplma.org/blog/24/East-Asia-Summit-leaders-endorse-
APLMA-Malaria-Elimination-Roadmap/).2. Quo Pacto?
This Latin phrase asks, ‘‘by what means?” The meaning of that
question in the context of this article does not refer to the social
and political assets needed to rally human energies and fiscal
resources to the cause of eliminating malaria in the Asia-Pacific
region. Instead, it is a technical question referring to the tangible
tools, tactics and strategies aimed at specific biological problems
to be engaged in that enterprise. If the important task of rallying
support for elimination is successful, how will those mobilised
resources be translated into significant gains against malaria in
the Asia-Pacific region? What tools will be brought to bear and
how? This article addresses these questions in the context of cru-
cially important differences between the malaria problem of Africa
and that of the Asia-Pacific region. In brief, the tools that have suc-
cessfully mitigated harm in Africa (RDTs, ACTS, LLINs, IRS) are
poorly suited to the task of eliminating malaria in the Asia-
Pacific region. Malaria here imposes obstacles to elimination not
shared with African malaria and few tools yet exist to cope with
those.
The elimination agenda must recognise and acknowledge
important biological distinctions between the African and Asian-
Pacific malaria problems. The means of eliminating malaria from
the Asia-Pacific region will necessarily be fundamentally distinct
from those of mitigating harm done by the relatively heavy bur-
dens of malaria in much of Africa. What are those distinctions
and by what means will humanity drive the plasmodia to extinc-
tion in the Asia-Pacific region? These questions will also be rele-
vant across the very long and wide fringes of the heavily
malarious heart of Africa – areas where there is relatively low
and more diverse ecologies of transmission.3. Singular, pervasive, diverse and invisible
The perception of malaria in the Asia-Pacific region as an essen-
tially similar but less serious problem than African malaria over-
simplifies it to an extraordinary degree. The two problems are
wholly distinct in biological, clinical, epidemiological and social
dimensions. Few commonalities link them beyond the role of
anopheline mosquitoes in conveying the plasmodia amongst
humans. A lay view of that limited commonality imposes the dan-
gerous risk of rote adoption of African strategies and tools in driv-
ing an Asian-Pacific malaria problem to elimination.
Understanding specific features of Asia-Pacific malaria that distin-
guish it from the dominant high burden African malaria is key to
formulating a rational elimination strategy.
The singular nature of Asia-Pacific malaria is its enormous
diversity and range relative to African malaria in terms of species
of parasites, their mosquito vectors, epidemiology, ecology of
transmission, parasite resistance to drugs, human genetics and
awareness of malaria as a serious problem. The following sum-
marise these distinctions.
3.1. Geographic distribution and burdens
Endemic malaria transmission occurs in almost all nations of
the Asia-Pacific region, excepting only Japan, Australia, New Zeal-
and and Singapore (Gething et al., 2012), and Sri Lanka recently
arrested endemic transmission (Fernando et al., 2015). Summing
up the populations living at risk of infection in those areas – withPlease cite this article in press as: Baird, J.K. Asia-Pacific malaria is singular,
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malaria-free – yields 2 billion versus 2.8 billion for all of humanity
(Gething et al., 2011). Transmission in the majority of those areas is
unstable or hypo-endemic – present but causing relatively few
cases per person-year compared with the intense holo-endemic
transmission occurring in much of sub-Saharan Africa. The burdens
of morbidity and mortality across the vast endemic expanse of the
Asia-Pacific region are exceedingly difficult to credibly estimate.
A study of malaria-attributable mortality in India illustrates the
uncertainties (Dhingra et al., 2010). Systematic verbal autopsy of
100,000 randomly selected deaths in a single year suggested
205,000 people lost their lives to malaria, 86% of them away from
treatment centres, in areas where diagnosis and reporting was
highly improbable. In that same year, the WHO estimated only
15,000 deaths due to malaria in India (Hay et al., 2010). The report
stirred controversy (Butler, 2010) and many in public health
rejected the findings as too extraordinary to be credible and cited
analytical pitfalls of verbal autopsy. The important point on mor-
tality due to malaria in the Asia-Pacific region is that uncertainty
– we don’t know the absolute burdens of morbidity and mortality
linked to malaria in the Asia-Pacific region. Either tens of millions
of infections occur with the loss of tens of thousands of lives, as
estimated by the WHO (World Health Organization, 2015), or sev-
eral hundred million cases occur with the loss of a few hundred
thousand lives as implied by the Indian mortality study.
The relatively low levels of transmission in the Asia-Pacific
region should not lull us into believing or hoping that absolute
morbidity and mortality burdens are also relatively low – the enor-
mous numbers of people composing denominators of risk for ill-
ness or death may conceal very substantial numbers of people
composing the numerators, the ill and dead.
3.2. Low intensity transmission
The task of bringing low transmission to zero is far more chal-
lenging than reducing high levels of transmission. A number of
key factors help explain this. High prevalence of microscopically-
or RDT-patent infection of blood is the rule in high transmission
settings. Meta-analyses consistently reveal an inverse correlation
between the proportion of sub-patent to patent parasitemias and
prevalence of infection (Cheng et al., 2015; Moreira et al., 2015;
Wu et al., 2015). As prevalence diminishes, the proportion of
sub-patent infections rises. The sensitivity of diagnostic methods
declines with the level of transmission. The exhaustive surveys of
7355 residents of rural areas of Thailand, Cambodia and Vietnam
by Imwong and colleagues (2015a) recorded prevalence at 4% by
RDT, 5% by expert microscopy and 20% by a highly sensitive PCR
technique. This problem of a highly prevalent asymptomatic and
sub-patent reservoir imposes one of the great challenges for elim-
ination – case detection and treatment cannot achieve impacts if
only one in five case is detected. The impact of mass screen and
treatment interventions wanes as the undiagnosed and untreated
sub-patent reservoir represents larger proportions of those
infected.
Without far more sensitive point-of-care diagnostic methods
than microscopy or current RDT technologies, targeted mass drug
administration campaigns may be necessary to attack this key
reservoir of infection and transmission (WHO, 2016). Those cam-
paigns, however, require more intensive surveillance activities
than are typically carried out, i.e., conducting the campaigns where
and when needed is by no means a trivial task (WHO, 2010). Per-
haps most important in the Asia-Pacific setting, the inclusion of
hypnozoitocide for mass treatment is not currently practical and
treatment strategies excluding that therapy have little or no
impact on the prevalence of Plasmodium vivax (Maude et al.,
2014). It may be implausible in a social sense to approach commu-pervasive, diverse and invisible. Int. J. Parasitol. (2016), http://dx.doi.org/
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but not all of them. In a public health strategic sense, attacking
malaria one species at a time is not sensible because it multiplies
the energies and resources required.
3.3. Dominance of P. vivax
Asia-Pacific malaria is dominated by P. vivax, and the region
accounts for >80% of the global burden (Mendis et al., 2001).
Although P. vivax occurs all across Africa, Duffy factor negativity
apparently suppresses transmission and prevalence. Relative to
the African P. falciparum problem, P. vivax on that continent occurs
as a public health problem only along the northern edges of the
Sahel, across the Horn, and the island of Madagascar (Howes
et al., 2015). The intense focus of humanity on the extraordinary
African malaria problem, and the relatively minor role of P. vivax
in it, in part explains the chronic neglect of this infection in malar-
iology over the past 60 years (Mendis et al., 2001; Baird, 2007;
Price et al., 2007). Another very important factor in that neglect
was the erroneous assignment of an intrinsically benign character
to the malaria caused by P. vivax. Evidence accrued over the past
decade affirms an often pernicious course with severe and fatal
outcomes associated with severe anaemia, severe thrombocytope-
nia, respiratory distress, renal or hepatic dysfunction,
seizures/coma and shock (Anstey et al., 2012; Baird, 2013). Thus,
even in the Asia-Pacific region, P. vivax has been deeply neglected
as a scientific, clinical and public health problem.
Specific features of the biology of P. vivaxmake it a more daunt-
ing problem than P. falciparum. It is less likely to be diagnosed by
an RDT (WHO, 2012). It is widely resistant to first-line therapy
with chloroquine in the Asia-Pacific region (Price et al., 2014). Its
hypnozoites are widely tolerant of standard primaquine therapy
against them (John et al., 2012), and strains in the region exhibit
some of the most aggressive relapse behaviours (Battle et al.,
2014). Moreover, extreme sensitivity to primaquine by variants
of relatively severe inherited glucose-6-phosphate dehydrogenase
(G6PD) deficiency disorder in humans dominates all across the
Asia Pacific region (Howes et al., 2012, 2013). Another distinct
problem with P. vivax is the inability to offer primaquine therapy
against relapse to 93 million at-risk and highly vulnerable preg-
nant women and their infants, together with several hundred mil-
lion G6PD-deficient patients living at risk (Dellicour et al., 2010;
Howes et al., 2012). These patients will require other treatments
or chemo-preventive drugs against relapse.
Strategies aimed at eliminating P. falciparum have virtually no
impact upon P. vivax because they exclude attack of a hypnozoite
reservoir absent in P. falciparum. In one recent study at the Thai-
Myanmar border, an estimated 96% of clinical attacks by P. vivax
originated from the latent liver stages (Adekunle et al., 2015), as
did >80% of clinical vivax malaria in a Papua New Guinea study
(Robinson et al., 2015). Inability to safely attack or manage the
enormous threat imposed by the hypnozoite reservoir of P. vivax
in the Asia-Pacific region bodes poorly for prospects of elimination
(Tanner et al., 2015). Doing so will require mobilising G6PD point-
of-care diagnostics to the periphery of care wherever this infection
occurs (Baird, 2015) and to conceive, optimise and validate strate-
gies for preventing relapses in those unable to receive hypnozoito-
cidal therapies.
3.4. Artemisinin-resistant P. falciparum
The problem of artemisinin-resistant P. falciparum emerged on
the Thai-Cambodian border a decade ago and now occurs all across
the Greater Mekong Sub-Region (http://www.who.int/malaria/
publications/atoz/status-rep-artemisinin-act-resistance-sept2015.
pdf?ua=1). Vigorous efforts to contain or eliminate this problemPlease cite this article in press as: Baird, J.K. Asia-Pacific malaria is singular,
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occur in Thailand, Cambodia, Laos and Vietnam (Imwong et al.,
2015b). In the public health arena, artemisinin resistance is
acknowledged as a dire threat to the African continent, now almost
wholly reliant upon ACTs and without a replacement therapy at
the ready (White, 2010). The urgency of containment or elimina-
tion in the region mobilised very substantial resources aimed at
doing so (Kolaczinski et al., 2014). The continuing spread and deep-
ening of artemisinin resistance, while threatening potentially
catastrophic loss of life at some point in the future in Africa, threat-
ens lives and elimination ambitions in the Asia-Pacific region
today. Alternative emergency therapies such as atovaquone-
proguanil are being applied to achieve cure, but the susceptibility
of that drug to rapid and complete onset of resistance by a single
point mutation in its target molecule renders it an extremely thin
line of defense against untreatable falciparum malaria. Mitigating
the harm done by P. falciparum, much less its elimination, requires
new therapies of proven and lasting efficacy against artemisinin-
resistant strains.
3.5. Zoonotic malarias
Infection of humans by the plasmodial parasite of southeast-
ern Asian macaques, Plasmodium knowlesi, is known to occur
throughout most of the region (Moyes et al., 2014). Most con-
firmed cases have come from case reports of travellers, but in
Malaysian Borneo where the problem was first described over a
decade ago (Singh et al., 2004), robust epidemiological studies
revealed it as the dominant cause of malaria cases (Singh and
Daneshvar, 2013). Similarly thorough studies have yet to be
undertaken elsewhere in the region, largely for want of the sub-
stantial funding needed to do so. The expertise needed is widely
available in the region, but the will and resources needed to
examine the problem are not.
Critical questions remain unanswered regarding the malaria
zoonoses of southeastern Asia: (i) How widespread is the prob-
lem? (ii) Are asymptomatic carriers present? (iii) Are other species
involved? (iv) Is human-to-human transmission of these species
occurring? In clinical studies done during the 1950s and 1960s,
experimental infections of humans with not only P. knowlesi but
also Plasmodium cynomolgi, Plasmodium inui, and Plasmodium fieldi
(all natural parasites of macaques, amongst others in southeastern
Asian monkeys and apes) successfully infected humans who then
infected mosquitoes that became infective to both humans and
monkeys (Coatney et al., 1971). These plasmodia also infect a vari-
ety of anopheline species and not solely those occurring naturally
in the forest habitats of macaques (Coatney et al., 1971). Biologi-
cally, human-to-human transmission in the wild is thus perfectly
plausible and perhaps even likely given that confirmed vectors
of human plasmodia in southeastern Asia also become naturally
infected by the monkey malaria species (Maeno et al., 2015).
Human-to-human transmission of these parasites may well be
occurring.
A single case report of a human naturally infected by P. cyno-
molgi (Ta et al., 2014) illustrates the vital importance of a great deal
more work on this problem. This species is very closely related to P.
vivax, including latency with dormant hypnozoites. Under the
microscope, it is morphologically indistinguishable from P. vivax,
and in that reported case reacted positively to standard nested
PCR primers for P. vivax. Absent the sequencing of those PCR ampli-
cons, the diagnosis would have been confirmed as P. vivax, and
absent more thorough investigations of scale, the proportion of
human P. vivax cases being P. cynomolgi remains an important
unknown. The scale of an animal reservoir of malaria in humans
is a conspicuously important and almost wholly neglected ques-
tion in the elimination agenda for the Asia-Pacific region.pervasive, diverse and invisible. Int. J. Parasitol. (2016), http://dx.doi.org/
4 J.K. Baird / International Journal for Parasitology xxx (2016) xxx–xxx3.6. Diversity of vectors and transmission ecology
Whereas a few species of anopheline mosquitoes of largely
shared ecologies and behaviours (dominated by the anthrophilic
and endophilic Anopheles gambiae, Anopheles funestrus, and
Anopheles arabiensis complexes) occur in highly endemic Africa,
several dozen confirmed vector species (many of them zoophilic
and exophilic) flourish across the Asia Pacific region in an enor-
mous variety of habitats and ecological settings (Sinka et al.,
2011, 2012). Starting with modest observational studies in the
1980s (Bradley et al., 1986), the next two decades saw the collec-
tion of hard evidence of diminished all cause mortality in Africa
by use of insecticide-bearing bed nets (Choi et al., 1995;
Lengeler, 2004). That evidence underpinned the massive distribu-
tions of many hundreds of millions of LLINs that then followed
(from about 2005 onwards). Very few randomised controlled trials
of LLINs have been done in Asia-Pacific region, and one of the most
thorough reported modest or no protective effects (Smithius et al.,
2013a). Those investigators attributed that outcome to observed
and recorded early evening and outdoor feeding preferences by
the anophelines present (Smithius et al., 2013b). Reliance upon
LLINs to eliminate malaria in the Asia-Pacific region rests upon
hope of efficacy rather than realised evidence.
3.7. Mobile and migrant populations
The relatively high density of human populations throughout
much of the Asia-Pacific region drives people to seek economic
opportunity away from their homes. That is, they are mobile and
migrant, and the region has a tradition of this lifestyle reaching
back centuries (http://www.migrationpolicy.org/article/migra-
tion-asia-pacific-region), including domestic migration. In India
up to 100 million people may be mobile and migrant within bor-
ders, most of them urban poor seeking seasonal work in agricul-
ture. Such movement, from a densely populated area of limited
economic opportunity to relatively unsettled frontiers with ende-
mic malaria transmission, may be typical of most seasonal
migrations.
Taking Indonesia as an example, millions of Javanese seek eco-
nomic opportunity amongst the still sparsely populated other
islands across this 5300 km archipelago. Most retain links to Java
and regularly return, sometimes bringing acute, sub-patent or
latent malaria with them (Elyazar et al., 2011; Sutanto et al.,
2013; Nelwan et al., 2015). A study of the movements of 91 million
cellular phones on Java revealed 17 million travelling to other
islands in Indonesia in a single year (Elyazar I, Eijkman-Oxford
Clinical Research Unit, Indonesia, personal communication).
Excepting sporadic outbreaks and a handful of stubborn low-
intensity foci of endemic transmission, Java is virtually free of
malaria (Elyazar et al., 2011). However, the island remains highly
receptive to malaria with at least several dangerous anopheline
vectors occurring in substantial numbers and across wide areas
(Anopheles sundaicus, Anopheles maculatus, Anopheles aconitus and
Anopheles balabacensis to name a few) (Elyazar et al., 2013). There
is little doubt that most of the chronic outbreaks regularly occur-
ring on Java derive from infected migrants. What is true for Indone-
sia is also regionally true – malaria elimination will require
strategies for coping with the threat of malaria imported by trav-
ellers and migrants into highly receptive areas, within and
between borders.
Those strategies have yet to be conceived, much less optimised
and validated. The tracking and treating of these migrants before
they transmit malaria seems highly implausible given the vast
numbers and geography. One solution may be a disciplined and
sustained implementation of anopheline species sanitation meth-
ods as a means of protecting malaria-free areas at high risk ofPlease cite this article in press as: Baird, J.K. Asia-Pacific malaria is singular,
10.1016/j.ijpara.2016.06.006importation. That forgotten art of malaria control achieved huge
impacts in the Netherlands East Indies and many other locations
before the age of IRS and LLINs (Takken et al., 1990; Keiser et al.,
2005). The lethal malaria epidemic at the Segera Anakan estuary
on the southern coast of Java in 1984 illustrates this danger:
imported malaria and environmental conditions suited to
An. sundaicus drove transmission (Atmosoedjono et al., 1992).
The Asia-Pacific region may need to again apply anopheline species
sanitation in order to prevent the reseeding of malaria-free areas
by hundreds of millions of mobile and migrant people.
3.8. Vaccination strategy
Almost all work on malaria vaccines over the past decades has
focused on preventing death in young Africans exposed to P. falci-
parum. Preventing infection per se fell away relatively early in that
endeavour as evidence mounted, indicating inability to do so with
available molecular subunit vaccine technologies. The sparing of
life, by rendering infections less likely to progress to death, by
effective vaccination is a sensible and worthy objective in the Afri-
can context. In the Asia-Pacific region an intervention that exacer-
bates the asymptomatic reservoir problem may not be suited to
elimination strategy. However, others argue that perhaps the
RTS,S vaccine could be useful in the Asia Pacific region (Gosling
and von Seidlein, 2016). A vaccine that prevents infection per se,
i.e., sterilising protection, is needed. If available, such a product
would likely find application in the problem of mobile and migrant
workers, i.e., vaccination of those at high risk of returning with
malaria, or of those resident in areas of high risk of reintroduced
malaria. At present, the only vaccine technology holding out such
promise is live attenuated sporozoite vaccines (Hoffman et al.,
2015). These ought to be optimised and validated in the context
of eliminating the Asia-Pacific malaria problem, including exami-
nation of the possibility of cross-species protection by a P. falci-
parum sporozoite vaccine (Sedegah et al., 2007).
3.9. Invisible malaria
The asymptomatic, sub-patent and latent reservoirs of malaria
give the term ‘invisible malaria’ a physical reality. Those malarias
dominate the epidemiological landscape of Asia-Pacific malaria.
But there is an important social dimension to the term as well. In
both lay and expert communities, the malaria problem of Asia-
Pacific region pales in comparison to that of Africa. The extraordi-
nary levels of transmission and exhaustive evidence documenting
mortality amongst infants and small children in Africa rivet inter-
national humanitarian attention on that problem. In the Asia-
Pacific region, malaria occurs amongst the most invisible people
within the many societies affected and the problem often exceeds
the public health capacities needed to take notice.
The Asia-Pacific region was home to 4.3 billion people in 2013
(http://www.unescapsdd.org/files/documents/SPPS-Factsheet-
Population-Trends-v3.pdf), 57% of them living in rural settings
(http://www.unescap.org/stat/data/syb2011/I-People/Urbanization.
asp). Although urban malaria transmission occurs in India, the
responsible vector, Anopheles stephensi, is largely absent from the
rest of region. No other anopheline species in the region tolerate
urban environments. Asia-Pacific malaria is thus overwhelmingly
a disease of those living in relatively isolated and impoverished
rural areas. The demographic example of the Indonesian archipe-
lago of 13,500 islands highlights this important fact (Fig. 1), where
150 million of its 250 million citizens live on just two islands, Java
and Bali. Whereas malaria transmission on Java and Bali is spo-
radic, isolated to very few low-grade foci, and nearly eliminated,
all of the other islands have stable endemic transmission in most
rural areas. Providing robust health services and surveillance allpervasive, diverse and invisible. Int. J. Parasitol. (2016), http://dx.doi.org/
Fig. 1. Maps illustrate inverse correlation of (A) population density in Indonesia (courtesy of Malaria Atlas Project, University of Oxford, UK and the Ministry of Health,
Republic of Indonesia) with (B) risk of malaria (reproduced with permission from Elyazar, I.R.F., Getting, P.W., Patil, A.P., Rogayah, H., Sariwati, E., Palupi, N.W., Tarmizi, S.N.,
Kusriastuti, R., Baird, J.K., Hay, S.I., 2012. Plasmodium vivax malaria endemicity in Indonesia in 2010. PLoS One 7(5) e37325. doi: http://dx.doi.org/10.1371/journal.pone.
0037325). The sparsely populated outer islands of the Indonesian archipelago are dominated by stable prevalent Plasmodium vivax (and Plasmodium falciparum (not shown)).
The islands of Java and Bali are home to 150 million of Indonesia’s 250 million citizens, and have no stable prevalent malaria transmission.
J.K. Baird / International Journal for Parasitology xxx (2016) xxx–xxx 5across the sparsely populated archipelago poses steep challenges
to the government. As in most developing nations, the rural poor
often live beyond the reach of routine clinical care and the systems
that monitor, count and report what ails them. The mortality study
from India (Dhingra et al., 2010) confirmed this by finding 86% of
deaths occurred away from treatment centres. Morbidity and mor-
tality, and its causes, go largely without investigation and report-
ing by severely stretched and limited clinical and public health
services. Epidemiologically sound surveillance of morbidity and
mortality and its causes may be essentially absent across large
swathes of the rural Asia-Pacific region.Please cite this article in press as: Baird, J.K. Asia-Pacific malaria is singular,
10.1016/j.ijpara.2016.06.006The absence of robust estimates of malaria morbidity and mor-
tality across most of the Asia-Pacific region lulls us dangerously to
accept it as evidence of relatively light absolute burdens amongst
the two billion people living at risk. The widely disregarded study
of malaria mortality in India (Dhingra et al., 2010) warns us to
gather materialised evidence. That report of an estimated
205,000 deaths due to malaria in India alone evoked criticisms of
methodologies and broad dismissal of the findings, thereby pre-
serving the status quo of the absence of evidence. An appropriate
refutation of seemingly scientifically valid study findings of such
gravity would be the materialised evidence of scientifically morepervasive, diverse and invisible. Int. J. Parasitol. (2016), http://dx.doi.org/
Table 1
Suite of tools needed for the elimination of malaria in the Asia-Pacific region.
Elimination tool Utility Status
Therapy for artemisinin-resistant Plasmodium
falciparum
Eliminating P. falciparum Phase II and III studies underway
Single-dose therapy against hypnozoites of
Plasmodium vivax
Attacking the hypnozoite reservoir Phase III studies (tafenoquine)
Point-of-care G6PD diagnostic device Safe access to hypnozoitocidal therapy At least one kit commercially available and promising
validation data (CareStart G6PDTM (AccessBio, USA))
Chemo-preventive strategies against relapse
without access to hypnozoitocidal therapy
Managing relapse risk in pregnant women, young infants,
G6PD deficient patients, and CYP2D6-disabled patients
Not conceived
Point-of-care diagnostic for all species of
Plasmodium with PCR-like sensitivity
Attacking the asymptomatic/sub-patent reservoir Several technologies in early development
Surveillance of malaria as a zoonosis Understanding the threat posed by an animal reservoir for
human malaria
Accomplished only in Malaysian Borneo
Species sanitation of anophelines Rendering malaria-receptive areas less vulnerable to
imported malaria
Technology abandoned over 70 years ago, almost
entirely not practiced
Surveillance and healthcare delivery capacities
reaching the most rural and isolated
populations
Access to monitoring and care by the most at-risk
populations
Limited by economics, technical capacities and
geography
Sterilising protective vaccination Dealing with mobile and migrant population risk of
reintroduced malaria
Live attenuated sporozoite vaccines in phase II
development
6 J.K. Baird / International Journal for Parasitology xxx (2016) xxx–xxxrobust mortality estimates of an order of magnitude lower. Failing
to do so, simple disbelief and dismissal registers as irrational con-
fidence or blind ignorance.4. Implications for elimination
Eliminating malaria from the Asia-Pacific region requires speci-
fic technical strategies and tools for coping with all of the unique
features of the problem summarised here. Unfortunately, most of
these strategies or tools have not yet been conceived and none
have been optimised and validated. Table 1 summarises these
requirements. Given the slow pace of even vigorously supported
clinical research agendas with bright prospects endowed by exist-
ing technologies, the vision of a malaria-free Asia-Pacific region by
2030 seems highly implausible in a technical sense. Some of the
key required technologies do not yet exist, e.g., a true point-of-
care diagnostic device offering PCR-like sensitivity of detection of
infection. Firm commitment to elimination in the Asia Pacific
region will require a great deal more patience and investments
in developing the technologies and tools needed, their optimisa-
tion and validation, and finally their systematic implementation
in robustly managed and executed programmes of elimination.
This requires acknowledging the inadequacy of African solutions
that mitigate that problem and recognising the unique require-
ments for malaria elimination in the Asia-Pacific region. Absent
such, the singular, pervasive, diverse and invisible problem of
malaria in the Asia-Pacific region will be a clinical and public
health battleground for generations to come.
The danger in spirited advocacy for elimination of Asia-Pacific
malaria by 2030 is the arrest of the hard work of developing the
very tools needed to achieve it. Young scientists in the region
may steer clear of what is perceived as a vanishing health problem.
Funding agencies may find investment in long-term development
of tools unattractive or irrational – a new class of hypnozoitocides,
for example, may take a decade ormore of relatively very expensive
work, only to emerge when presumably no longer needed. If the
year 2030 arrives and the plasmodia have yet to be eliminated from
the region, we may find deferred investments in people and techni-
cal progresswill have ensured the inability to be rid of this problem.
Malaria is a formidable foe, especially in the Asia-Pacific region.
A vision of eliminating the plasmodia that excludes the technical
means of doing so should be acknowledged as dangerous hubris.
These parasites will not surrender to human will alone, but to
human ingenuity aimed at highly specific technologically defined
points of deliberate and sustained biological attack on them. Con-Please cite this article in press as: Baird, J.K. Asia-Pacific malaria is singular,
10.1016/j.ijpara.2016.06.006ceiving those strategies and tools, optimising and validating them,
and finally aggressively implementing them should be the focus of
the earnest will to drive the plasmodia to extinction in the Asia-
Pacific region.
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